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of subjects victims of alopecia. Furthermore, 18.2% suf-
fer from anxiety, 3,5% presented a social phobia and
4,4% paranoia. All these rates are above those noticed
with the general population. CONCLUSION: These dif-
ferent results underline the necessity for assessing the psy-
chological and even psychiatric consequences of hair loss
for patients suffering alopecia. Demonstration is done
that these patients need to have a relevant psychological
help from their practitioners, who are very often them-
selves relying on the outside help of a pharmacological
nature for assisting their work.
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OBJECTIVE: A single course of treatment with Assisted
Reproduction Techniques (ART) may be viewed as in-
complete treatment for the majority of infertile couples.
A realistic comparison of both costs and therapeutic con-
sequences must consider the cumulative costs of achiev-
ing an ongoing pregnancy after several cycles of treat-
ment using Recombinant FSH (rFSH) or urinary FSH
(uFSH). METHOD: A cost-effectiveness analysis included
the Markov model and Monte-Carlo simulations. Infor-
mation on costs and probabilities were provided by na-
tional formulary costs and clinic tariff, a meta-analysis
(of randomized clinical trials), randomized controlled
clinical trials, medical literature and national registries.
All the data were validated by a panel of international ex-
perts. Because estimates for key clinical data will vary de-
pending on the source, the estimates of variability among
the transition probabilities were ratified by the expert
panel according to UK experience. This approach pro-
vided a distribution of transition probabilities from which
a precise standard deviation could be obtained for each
outcome. The final Markov matrix included about 200
health states, computerized with a specific Pascal pro-
gram, which covered the complete ART process includ-
ing both fresh and cryopreserved embryos. RESULTS:
After running 5000 simulations on a virtual population
of 100,000 patients the results are: Total number of suc-
cesses (pregnancy): 40,575 for rFSH and 37,358 for
uFSH. Cost/success: £5906 (SD  £232) for rFSH and
£6060 (SD  £279) for uFSH. Mean number of cycles/
success: 4.59 for rFSH and 5.25 for uFSH. CONCLU-
SION: Recombinant FSH is more effective and more
cost-effective than urinary derived FSH.
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OBJECTIVE: To identify the quality of life (QoL) dimen-
sions relevant for men who currently take sildenafil to
treat erectile dysfunction (ED) and to evaluate the impact
of sildenafil use on these QoL dimensions. QoL studies
can be a valuable tool for healthcare decision-makers as
they assess the relative benefits and costs of sildenafil
treatment for ED. METHODS: 500 men taking sildenafil
were interviewed, using a structured questionnaire specif-
ically developed for this study. Each had been diagnosed
with ED by a physician. The respondents were asked to
rate the extent to which sildenafil had affected both phys-
ical and emotional aspects of their life. RESULTS: Fifty-
two percent had been taking sildenafil for more than 1
year. Eighty-six percent of the participants were married.
Of the remaining 14%, 69% reported being in a commit-
ted relationship. The overall results indicate that QoL
measures were high in men receiving sildenafil. The re-
spondents (average age 62) reported that the QoL dimen-
sions where sildenafil had the most impact were confi-
dence, relationship with partner, sex life, and life overall.
Sixty percent reported that they felt more confident after
treating their ED with sildenafil. Eighty-two percent re-
ported an improvement in their relationships with part-
ners; 75% reported an improvement in their sex lives;
and 66% reported an improvement in their overall lives.
CONCLUSION: The results suggest that use of sildenafil
to treat ED has a positive impact on patient’s lives. The re-
sults also suggest that additional investigation into identi-
fying relevant QoL items and domains for ED is war-
ranted since this impact has been undetected by currently
available QoL instruments.
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OBJECTIVE: The scoring of the Women’s Health Ques-
tionnaire (WHQ) was reviewed as part of the Interna-
tional Health-related Quality of Life Database (IQOD)
program. New hypotheses on item grouping were con-
firmed in different translated versions of the WHQ. Using
this new conceptual model, reference values were devel-
oped per country and in different populations. METHODS:
The scoring of the WHQ was reviewed using data from
different countries: UK, US, France, Germany, Italy, Po-
land. The 23-item WHQ measures QoL in women, and
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investigates 6 domains: anxiety/depressed mood, well-be-
ing, somatic symptoms, memory/concentration, vasomo-
tor symptoms, and sleep problem. Two optional modules
evaluate sexual behavior and menstrual symptoms. A
score is calculated for each domain and each optional
module. Scores have been calculated using this new scor-
ing. Psychometric properties of the translated versions
using the new scoring were tested. The analyses used in-
cluded: 1) Multitrait analysis (MA) to confirm the con-
struct validity of the proposed model; 2) Cronbach al-
pha’s coefficient to assess internal consistency reliability;
3) Distribution of correlation of scores according to clini-
cal criteria to assess discriminative power of the question-
naire. RESULTS: Results of MA per country data showed
that all items were more correlated to their own scale
than with the other scales, thus providing evidence of
good construct validity. Cronbach’s alpha was found to
be above 0.70 for all dimension in all countries. Scores
were found to be significantly correlated to clinical crite-
ria such as severity of hot flushes and insomnia. Post-
menopausal women reported lower scores than peri and
pre-menopausal women, indicating lower level of QoL
on all scales except menstrual symptoms (P  0.05, Kruskal-
Wallis test). CONCLUSION: The scores obtained from
this research can be used as reference values when using
the WHQ in the UK, US, France, Germany, Italy, Poland.
These reference values will facilitate the interpretation
and understanding of the cross-cultural research using
the WHQ questionnaire.
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OBJECTIVES: An issue in economic evaluation is whose
preferences should be used to determine the value weights
for different health states: values of patients or of the
general public. In the economic evaluation of sildenafil
we were particularly afraid that differences in values be-
tween those two groups would influence the outcomes, as
a consequence of selection and strategic bias, or un-
awareness of the general public of problems related to
erectile dysfunction. We therefore examined the differ-
ences between patients’ values and values of the general
public. METHODS: In a MANOVA repeated measure
analysis we compared the values for the different states
of erectile dysfunction elicited in patients and the general
public. In the analysis we had to deal with opposite bi-
ases. We assumed that strategic or selection bias in pa-
tients would result in lower means, and that differences
in the correlation structure would indicate unawareness
in the general public about the ways in which erectile
dysfunction impairs quality of life. Therefore, when dif-
ferent means occurred, we would still consider the soci-
etal perspective valid as long as there are no significant
differences between patients and the general public with
regard to correlation structure among the values. RE-
SULTS: Patients valued erectile dysfunction lower than
the general public. This result can probably not be attrib-
uted to unawareness of the condition in the general pub-
lic, because the factor structure did not differ. CONCLU-
SIONS: For the appraisal of treatment effects of erectile
dysfunction, societal values should be used. Patients’ val-
ues seem most strongly biased by the fact that they are
currently involved in the trial, resulting in a strategic and
selection bias, which underestimates the current quality
of life.
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OBJECTIVE: Even though Health-related Quality of Life
(HRQL) instruments are increasingly being used, there is
a lack of standardization of administration, interpreta-
tion, and understanding of cross-cultural issues. The ob-
jective of the International Health-related Quality of Life
Outcomes Database (IQOD) program is to further the
methodology of assessing conceptual equivalence of trans-
lated versions and apply this methodology to major
HRQL questionnaires, such as the WHQ. METHODS:
Hypothesized structure of the questionnaire as defined by
its developer was first examined using principal compo-
nent analysis (PCA) and multitrait analysis (MA). These
analyses were performed on the original language version
to test the hypothesized model. The model was then ap-
plied to each language version to evaluate any potential
differences and to provide validation evidence of their
psychometric properties. Data was collected from 4 stud-
ies (observational studies and clinical trials) in the UK,
US, France, Germany, Italy, and Poland. The population
consisted of 9023 peri, pre or post-menopausal women.
RESULTS: The results of PCA and MA on country data
showed that the hypothesized item grouping was not re-
spected. In order to achieve conceptually equivalent trans-
lated versions, a new scoring was developed in collabora-
tion with the developer. This new scoring was applied to
the UK data using Confirmatory Factorial Analysis and
showed that the model was correct (N  811, Chi2 
618.6, normed fit index (NFI)  0.89, goodness of fit in-
dex (GFI)  0.94). The same model was applied to the
pooled sample and fit well (N  6047, Chi2  5715.6,
NFI  0.88, GFI  0.90). Calculation of Cronbach’s al-
pha (	0.70 for all countries) and evaluation of item con-
vergent and divergent criteria showed good internal con-
sistency and construct validity of the translated versions.
CONCLUSION: The methodology used in this program
can be applied to other questionnaires in evaluating
cross-cultural equivalence and thus facilitating interpre-
tation of multi-national studies.
